{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:47:03Z","timestamp":1782218823415,"version":"3.54.5"},"reference-count":57,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM113940"],"award-info":[{"award-number":["R01GM113940"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Photochem &amp; Photobiology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In situ photo\u2010vaccination (ISPV) is a promising cancer immunomodulation strategy that combines photodynamic therapy (PDT) with targeted release of chemotherapy to transform tumors into personalized vaccines. However, its efficacy in controlling established, larger distal tumors remains limited, reflecting a significant challenge among therapeutic cancer vaccines. To address this, we used a bilateral Colon 26 murine tumor model to systematically optimize ISPV parameters, including drug\u2010light interval, paclitaxel prodrug dose, light dose, size of the illuminated tumor (related to antigen dose), and checkpoint blockade, and to link these to cellular mechanisms of immunogenic cell death. A low prodrug dose (0.5\u2009\u03bcmol\/kg compared to ~24\u2009\u03bcmol\/kg of Paclitaxel in mice) and a fluence rate of 75\u2009mW\/cm\n                    <jats:sup>2<\/jats:sup>\n                    for 30\u2009min with a 30\u2010min drug\u2010light interval produced the strongest systemic responses. Abscopal efficacy was strongly linked to antigen dose: treating larger primary tumors expedited control of distant tumors, allowing the suppression of untreated tumors to a size comparable to the primary tumor. Checkpoint inhibition with anti\u2010CTLA\u20104 was essential, as its removal eliminated distant tumor control. Importantly, optimized ISPV reproducibly controlled distant tumors of a size equivalent to the treated primary, an outcome rarely achieved with other in\u00a0situ vaccination approaches. These findings establish a mechanistically informed framework for PDT\u2010driven ISPV and provide a strong rationale for translation of this strategy to the treatment of metastatic cancer.\n                  <\/jats:p>","DOI":"10.1111\/php.70124","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:48:41Z","timestamp":1782215321000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single\u2010treatment in\u00a0situ photo\u2010vaccination with paclitaxel prodrug\u2010\n                    <scp>PDT<\/scp>\n                    enables durable local and abscopal tumor control in a bilateral Colon 26 model"],"prefix":"10.1111","author":[{"given":"Kazi Md Mahabubur","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Dsouza","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7078-0990","authenticated-orcid":false,"given":"Soniya","family":"Kumbham","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-1347","authenticated-orcid":false,"given":"Prabhanjan","family":"Giram","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bist","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukyung","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wohlfert","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University at Buffalo School of Medicine  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine University at Buffalo  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjae","family":"You","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, The State University of New York  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"26","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD\u20101 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD\u20101\/PD\u2010L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun J\u2010Y","year":"2020","journal-title":"Biomark Res"},{"issue":"5","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies M","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2217\/imt.15.120","article-title":"In situ vaccination for the treatment of cancer","volume":"8","author":"Hammerich L","year":"2016","journal-title":"Immunotherapy"},{"issue":"51","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","article-title":"In situ vaccination by radiotherapy to improve responses to anti\u2010CTLA\u20104 treatment","volume":"33","author":"Vanpouille\u2010Box C","year":"2015","journal-title":"Vaccine"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omto.2020.04.006","article-title":"In situ therapeutic cancer vaccination with an oncolytic virus expressing membrane\u2010tethered IL\u20102","volume":"17","author":"Liu W","year":"2020","journal-title":"Molecular Therapy \u2013 Oncolytics"},{"issue":"11","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/vaccines13111114","article-title":"In situ vaccination by tumor ablation: principles and prospects for systemic antitumor immunity","volume":"13","author":"Chikovani T","year":"2025","journal-title":"Vaccine"},{"issue":"12","key":"e_1_2_10_10_1","article-title":"Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy","volume":"3","author":"Adkins I","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"3","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1039\/c3pp50333j","article-title":"ER stress, autophagy and immunogenic cell death in photodynamic therapy\u2010induced anti\u2010cancer immune responses","volume":"13","author":"Garg AD","year":"2014","journal-title":"Photochem Photobiol Sci"},{"issue":"12","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3390\/cancers13122992","article-title":"Photodynamic therapy: targeting cancer biomarkers for the treatment of cancers","volume":"13","author":"Wang X","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova J","year":"2020","journal-title":"Cell Death Dis"},{"issue":"1","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak R","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijrobp.2024.09.024","article-title":"Antiangiogenic treatment facilitates the abscopal effect of radiation therapy combined with anti\u2010PD\u20101 in hepatocellular carcinoma","volume":"121","author":"Sheng H","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106947","article-title":"Th1 adjuvant ARNAX, in combination with radiation therapy, enhances tumor regression in mouse tumor\u2010implant models","volume":"271","author":"Miyazaki A","year":"2025","journal-title":"Immunol Lett"},{"issue":"23","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-19-1344","article-title":"Cisplatin facilitates radiation\u2010induced abscopal effects in conjunction with PD\u20101 checkpoint blockade through CXCR3\/CXCL10\u2010mediated T\u2010cell recruitment","volume":"25","author":"Luo R","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100823","article-title":"CpG\u2010coated prussian blue nanoparticles\u2010based photothermal therapy combined with anti\u2010CTLA\u20104 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma","volume":"13","author":"Cano\u2010Mejia J","year":"2020","journal-title":"Transl Oncol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2018.02170","article-title":"Anti\u2010glucocorticoid\u2010induced tumor necrosis factor\u2013related protein (GITR) therapy overcomes radiation\u2010induced Treg immunosuppression and drives abscopal effects","volume":"9","author":"Schoenhals JE","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005834","article-title":"In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade","volume":"10","author":"Mao C","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-02245-3","article-title":"Systemic tumor regression with synergy therapy: radiotherapy and CAR\u2010T","volume":"10","author":"Ma X","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/php.14025","article-title":"Prodrugs of paclitaxel improve in\u00a0situ photo\u2010vaccination","volume":"101","author":"Giram P","year":"2025","journal-title":"Photochem Photobiol"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03165-x","article-title":"Novel engineered IL\u20102 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti\u2010tumor responses of radiation therapy","volume":"43","author":"He K","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single\u2010dose radiotherapy induces an immune\u2010mediated abscopal effect when combined with anti\u2013CTLA\u20104 antibody","volume":"15","author":"Dewan MZ","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/cancers15092471","article-title":"Metronomic chemotherapy: anti\u2010tumor pathways and combination with immune checkpoint inhibitors","volume":"15","author":"Muraro E","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1479-5876-7-58","article-title":"Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations","volume":"7","author":"Kaneno R","year":"2009","journal-title":"J Transl Med"},{"issue":"1","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ijc.2910530126","article-title":"Effect of drug\u2010light interval on photodynamic therapy with meta\u2010tetrahydroxyphenylchlorin in malignant mesothelioma","volume":"53","author":"Ris H\u2010B","year":"1993","journal-title":"Int J Cancer"},{"issue":"1","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"11667","DOI":"10.1038\/s41598-023-38862-8","article-title":"Photodynamic therapy changes tumour immunogenicity and promotes immune\u2010checkpoint blockade response, particularly when combined with micromechanical priming","volume":"13","author":"Lobo CS","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/jcm9010104","article-title":"Immune responses after vascular photodynamic therapy with Redaporfin","volume":"9","author":"AC SL","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1021\/acs.jmedchem.5b01971","article-title":"Far\u2010red light\u2010activatable prodrug of paclitaxel for the combined effects of photodynamic therapy and site\u2010specific paclitaxel chemotherapy","volume":"59","author":"Thapa P","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans DEJGJ","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3390\/pharmaceutics15112617","article-title":"Photodynamic therapy\u2010induced anti\u2010tumor immunity: influence factors and synergistic enhancement strategies","volume":"15","author":"Chou W","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc1894","article-title":"Photodynamic therapy and anti\u2010tumour immunity","volume":"6","author":"Castano AP","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/imr.12573","article-title":"Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences","volume":"280","author":"Brix N","year":"2017","journal-title":"Immunol Rev"},{"issue":"4","key":"e_1_2_10_35_1","first-page":"233","article-title":"The abscopal effect in patients with cancer receiving immunotherapy","volume":"4","author":"Nelson BE","year":"2023","journal-title":"Fortschr Med"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1011943","article-title":"Impact of mouse model tumor implantation site on acquired resistance to anti\u2010PD\u20101 immune checkpoint therapy","volume":"13","author":"Denis M","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4161\/cbt.8.4.7452","article-title":"Alternative site of implantation affects tumor malignancy and metastatic potential in mice: its comparison to the flank model","volume":"8","author":"Speroni L","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/sj.bjc.6690123","article-title":"Tumour inoculation site\u2010dependent induction of cachexia in mice bearing colon 26 carcinoma","volume":"79","author":"Matsumoto T","year":"1999","journal-title":"Br J Cancer"},{"issue":"4","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002107","article-title":"Depth of tumor implantation affects response to in\u00a0situ vaccination in a syngeneic murine melanoma model","volume":"9","author":"Carlson PM","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5114\/ceji.2015.56974","article-title":"Immunological aspects of antitumor photodynamic therapy outcome","volume":"40","author":"Wachowska M","year":"2015","journal-title":"Cent Eur J Immunol"},{"issue":"1","key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA\u20104 and PD\u20101 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder EI","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1142\/S1088424619300180","article-title":"Vascular targeted photodynamic therapy: a review of the efforts towards molecular targeting of tumor vasculature","volume":"23","author":"Mashayekhi V","year":"2019","journal-title":"J Porphyrins Phthalocyanines"},{"issue":"1","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"12655","DOI":"10.1038\/s41598-019-49064-6","article-title":"Effects of photodynamic therapy with Redaporfin on tumor oxygenation and blood flow in a lung cancer mouse model","volume":"9","author":"Karwicka M","year":"2019","journal-title":"Sci Rep"},{"issue":"13","key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ejca.2015.06.002","article-title":"Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens","volume":"51","author":"Rocha LB","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00262-014-1633-9","article-title":"Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease","volume":"64","author":"Shams M","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41416-024-02844-y","article-title":"Fractionated photoimmunotherapy stimulates an anti\u2010tumour immune response: an integrated mathematical and in\u00a0vitro study","volume":"131","author":"Zahid MU","year":"2024","journal-title":"Br J Cancer"},{"issue":"11","key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech SM","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry EJ","year":"2011","journal-title":"Nat Immunol"},{"issue":"79","key":"e_1_2_10_49_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6612","article-title":"Selective STING stimulation in dendritic cells primes antitumor T cell responses","volume":"8","author":"Jneid B","year":"2023","journal-title":"Sci Immunol"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fimmu.2019.00503","article-title":"TLR3 activation of Intratumoral CD103(+) dendritic cells modifies the tumor infiltrate conferring anti\u2010tumor immunity","volume":"10","author":"Roselli E","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"e_1_2_10_51_1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146608","article-title":"Coimmunomodulation of tumor and tumor\u2010draining lymph nodes during in\u00a0situ vaccination promotes antitumor immunity","volume":"7","author":"Jeong M","year":"2022","journal-title":"JCI Insight"},{"issue":"11","key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T\u2010cell infiltration","volume":"11","author":"Liu YT","year":"2021","journal-title":"Theranostics"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.573141","article-title":"Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma","volume":"10","author":"Kang K","year":"2020","journal-title":"Front Oncol"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi\u2010omics characterization of the 4T1 murine mammary gland tumor model","volume":"10","author":"Schr\u00f6rs B","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"e_1_2_10_55_1","doi-asserted-by":"crossref","first-page":"19940","DOI":"10.1038\/s41598-025-04715-9","article-title":"Mathematical mechanistic model representing the cancer immunity cycle under radiation effects","volume":"15","author":"Takayanagi T","year":"2025","journal-title":"Sci Rep"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7554\/eLife.70130","article-title":"Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling","volume":"10","author":"Butner JD","year":"2021","journal-title":"elife"},{"issue":"1087","key":"e_1_2_10_57_1","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170857","article-title":"Mathematical modelling of the synergistic combination of radiotherapy and indoleamine\u20102,3\u2010dioxygenase (IDO) inhibitory immunotherapy against glioblastoma","volume":"91","author":"Chakwizira A","year":"2018","journal-title":"Br J Radiol"},{"issue":"3","key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt.1987","article-title":"Quantitative systems pharmacology approaches for Immuno\u2010oncology: adding virtual patients to the development paradigm","volume":"109","author":"Chelliah V","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Photochemistry and Photobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/php.70124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/php.70124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/php.70124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:48:49Z","timestamp":1782215329000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/php.70124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":57,"alternative-id":["10.1111\/php.70124"],"URL":"https:\/\/doi.org\/10.1111\/php.70124","archive":["Portico"],"relation":{},"ISSN":["0031-8655","1751-1097"],"issn-type":[{"value":"0031-8655","type":"print"},{"value":"1751-1097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2026-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"php.70124"}}